Clinical Trial Update: Analysis of Letrozole in Patients With Operable Hormone Receptor Positive, HER2 Negative Breast Cancer

View source ↗

Summary

The document provides an update on an analysis of letrozole in operable HR-positive, HER2-negative breast cancer, noting the trial status as terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• FEMARA (letrozole)

Snippet

Sponsor: Mayo Clinic | Conditions: Breast Adenocarcinoma, Invasive Breast Carcinoma | Status: TERMINATED